This includes the downregulation of key cytokines such as interleukin-17 (IL-17), chemokine ligand 3 (CCL3), C-X-C motif chemokine 11 (CXCL11), and chemokine ligand 5 (CCL5) [18], providing a theoretical basis for targeting IGSF11 in cancer immunotherapy (Figure 4). The gene discussed is IL17A; the disease is cancer.